HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity's custodial revenue experienced a robust year-over-year growth of 13%, contributing to an adjusted EBITDA margin of 44%, reflecting a 466 basis point improvement. The company's cash flow from operations saw a significant increase of 28.4%, reaching $339.2 million in FY/26, which underscores the operational efficiency and financial health of the organization. Additionally, total revenue for Q3/26 rose by 7.2% to $322.2 million, driven by strong custodial revenue growth and a total HSA asset value that reached $36.5 billion, marking a 13.6% increase year-over-year, indicating enhanced consumer engagement and a favorable outlook for growth.

HealthEquity's revenue guidance for FY/27 has been revised downwards to $1.410 billion, reflecting a growth rate of only 7.4% year-over-year, indicating potential challenges in sustaining higher growth levels amid a highly competitive market. Additionally, despite a modest increase in adjusted EBITDA expectations, the company's valuation remains concerning, trading at multiples that exceed those of its high-growth SaaS peers, suggesting it may be overvalued relative to its growth trajectory. Furthermore, various external risks—including regulatory changes, potential cyber threats, and challenges in customer retention—further contribute to a negative outlook on the company's stock performance.